Literature DB >> 4402375

Azulfidine agranulocytosis with bone marrow, megakaryocytosis, histiocytosis and plasmacytosis.

K Jamshidi, T Arlander, M C Garcia, H W Windschitl, W R Swaim.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4402375

Source DB:  PubMed          Journal:  Minn Med        ISSN: 0026-556X


× No keyword cloud information.
  8 in total

1.  Bone marrow necrosis after treatment with sulphasalazine.

Authors:  J E Van de Pette; D T Cunnah; T M Shallcross
Journal:  Br Med J (Clin Res Ed)       Date:  1984-09-29

Review 2.  Sulfasalazine. Adverse effects and desensitization.

Authors:  S L Taffet; K M Das
Journal:  Dig Dis Sci       Date:  1983-09       Impact factor: 3.199

Review 3.  Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.

Authors:  S B Hanauer; G Stathopoulos
Journal:  Drug Saf       Date:  1991 May-Jun       Impact factor: 5.606

Review 4.  Clinical pharmacokinetics of sulphasalazine.

Authors:  K M Das; R Dubin
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

Review 5.  Comparative tolerability of treatments for inflammatory bowel disease.

Authors:  R B Stein; S B Hanauer
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

6.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

Authors:  D Rachmilewitz
Journal:  BMJ       Date:  1989-01-14

7.  Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

Authors:  A K Azad Khan; D T Howes; J Piris; S C Truelove
Journal:  Gut       Date:  1980-03       Impact factor: 23.059

Review 8.  Sulphasalazine: a review of 40 years' experience.

Authors:  G Watkinson
Journal:  Drugs       Date:  1986       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.